DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and
Markets
(http://www.researchandmarkets.com/research/qcdj5m/rnai)
has announced the addition of Jain PharmaBiotech's new report "RNAi
- Technologies, Markets and Companies" to their offering.
Because of its ability to silence any gene once the sequence is
known, RNAi has been adopted as the research tool to discriminate
gene function. After the genome of an organism is sequenced, RNAi
can be designed to target every gene in the genome and target for
specific phenotypes. Several methods of gene expression analysis
are available and there is still need for sensitive methods of
detection of gene expression as a baseline and measurement after
gene silencing. RNAi microarray has been devised and can be
tailored to meet the needs for high throughput screens for
identifying appropriate RNAi probes. RNAi is an important method
for analyzing gene function and identifying new drug targets that
uses double-stranded RNA to knock down or silence specific genes.
With the advent of vector-mediated siRNA delivery methods it is now
possible to make transgenic animals that can silence gene
expression stably. These technologies point to the usefulness of
RNAi for drug discovery.
RNAi can be rationally designed to block the expression of any
target gene, including genes for which traditional small molecule
inhibitors cannot be found. Areas of therapeutic applications
include virus infections, cancer, genetic disorders and
neurological diseases. Research at academic centers that is
relevant to RNAi-based therapeutics is mentioned.
Regulatory, safety and patent issues are discussed. Side effects
can result from unintended interaction between an siRNA compound
and an unrelated host gene. If RNAi compounds are designed poorly,
there is an increased chance for non-specific interaction with host
genes that may cause adverse effects in the host. However, there
are no major safety concerns and regulations are in preliminary
stages as the clinical trials are still ongoing and there are no
marketed products. Many of the patents are still pending.
The markets for RNAi are difficult to define as no RNAi-based
product is approved yet but several are in clinical trials. The
major use of RNAi reagents is in research but it partially overlaps
that of drug discovery and therapeutic development. Various markets
relevant to RNAi are analyzed from 2014 to 2024. Markets are also
analyzed according to technologies and use of siRNAs, miRNAs,
etc.
Profiles of 161 companies involved in developing RNAi technologies
are presented along with 233 collaborations. They are a mix of
companies that supply reagents and technologies (nearly half of
all) and companies that use the technologies for drug discovery.
Out of these, 33 are developing RNAi-based therapeutics and 35 are
involved in microRNAs. The bibliography contains selected 600
publications that are cited in the report. The text is supplemented
with 38 tables and 12 figures.
Key Topics Covered:
Executive Summary
1. Technologies for suppressing gene function
2. RNAi Technologies
3. MicroRNA
4. Methods of delivery in RNAi
5. RNAi in Research
6. RNAi in drug discovery
7. Therapeutic applications of RNAi
8. Safety, regulatory and patent issues
9. Markets for RNAi Technologies
10. Companies involved in RNAi Technologies
11. References
For more information visit
http://www.researchandmarkets.com/research/qcdj5m/rnai
Source: Jain PharmaBiotech
Media Contact: Laura Wood
, +353-1-481-1716, press@researchandmarkets.net